! Big Board Breakout Bulls (AMEX, NASDAQ and NYSE) !

[PennyStockInvestor]

The World Will Be Watching BPAX Come Feb. 14th.

Reason why to buy and hold BPAX through Feb. 14th
BPAX is partnered with TEVA
TEVA knows drugs and how to get them approved.


BPAX Bio-T Gel up for FDA approval on Feb. 14th 2012!
BPAX is extremely oversold currently trades between .65-.70cents price per share range. Potential to make huge gains on BPAX stock in only 2 short weeks. The price should start to uptrend as we get closer to Feb. 14th. Now is the time to buy. Don't miss the boat on this trying to get a cheaper price that will never come.

Biosante Pharmaceuticals Inc.

BPAX

Bio-T-Gel (NDA)

FDA decision on Bio-T-Gel for treatment of male hypogonadism or low testosterone levels

http://www.rttnews.com/corpinfo/fdacalendar.aspx



BPAX 14th Annual BIO CEO & Investor Conference, Feb-14-2012 10:30 AM
IMO they would not be presenting unless they had something new to report - this is a very good sign.


BPAX Conference Schedule

BioSante Pharmaceuticals, Inc. Presents at Biotechnology Industry Organization's 14th Annual BIO CEO & Investor Conference, Feb-14-2012 10:30 AM

BioSante Pharmaceuticals, Inc. Presents at Citi Global Healthcare Conference 2012, Feb-27-2012 03:30 PM

BioSante Pharmaceuticals, Inc. Presents at 24th Annual OC Growth Stock Conference, Mar-11-2012

BioSante Pharmaceuticals, Inc. expected to report Fiscal Year 2011 results on March 15, 2012. This event was calculated by Capital IQ (Created on July 28, 2011).

http://www.weseed.com/company/bpax-biosante-pharmaceuticals-inc


BPAX filed a patent application yesterday.

Inventors: Stephen Simes (Long Grove, IL, US) Michael Snabes (Winnetka, IL, US) Joanne Zborowski (Lake Zurich, IL, US)
Assignees: BIOSANTE PHARMACEUTICALS, INC.
IPC8 Class: AA61K3156FI
USPC Class: 514178
Class name: Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system
Publication date: 01/26/2012
Patent application number: 20120022033

Read More - http://www.faqs.org/patents/app/20120022033#ixzz1kbVvj5sz